|
gptkbp:instanceOf
|
inhalational anesthetic
halogenated ether
|
|
gptkbp:approvalYear
|
1979
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:aroma
|
mild, ether-like
|
|
gptkbp:ATCCode
|
N01AB06
|
|
gptkbp:boilingPoint
|
48.5 °C
|
|
gptkbp:CASNumber
|
26675-46-7
|
|
gptkbp:color
|
colorless
|
|
gptkbp:contraindication
|
hypersensitivity
malignant hyperthermia susceptibility
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:density
|
1.496 g/cm³
|
|
gptkbp:discoveredBy
|
gptkb:Ross_Terrell
|
|
gptkbp:discoveredIn
|
1965
|
|
gptkbp:eliminationHalfLife
|
0.2 hours
|
|
gptkbp:excretion
|
lungs
|
|
gptkbp:hasInChIKey
|
DZLVTNWLSHSOFT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C3H2ClF5O
|
|
gptkbp:hasSMILES
|
CC(OC(F)(F)Cl)F
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
isoflurane
|
|
gptkbp:KEGGID
|
D00419
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits NMDA receptor activity
potentiates GABA-A receptor activity
inhibits neuronal ion channels
|
|
gptkbp:meltingPoint
|
-140 °C
|
|
gptkbp:metabolism
|
minimal (0.2%)
|
|
gptkbp:minimumAlveolarConcentration
|
1.15% (in adults)
|
|
gptkbp:molecularWeight
|
184.5 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
3632
3763
CHEMBL1200697
DB00753
|
|
gptkbp:relatedTo
|
gptkb:desflurane
gptkb:enflurane
sevoflurane
halothane
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
malignant hyperthermia
hypotension
respiratory depression
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
CYS9AKD70P
|
|
gptkbp:usedFor
|
general anesthesia
|
|
gptkbp:usedIn
|
veterinary anesthesia
human anesthesia
|
|
gptkbp:vaporPressure
|
238 mmHg (at 20°C)
|
|
gptkbp:bfsParent
|
gptkb:Halothane
gptkb:Norflurane
gptkb:Desflurane
|
|
gptkbp:bfsLayer
|
8
|